TAMPA, Fla.–(BUSINESS WIRE)–Virtus
Pharmaceuticals, Inc., a specialty niche pharmaceutical company, and
part of the Linden Capital Partners (“Linden”) portfolio, today
announced it has launched Prometrium®
(Progesterone, USP Capsules). This is Virtus’ first branded product.
Prometrium® complements an already strong product portfolio of products,
which includes a focus on Women’s Health.
“With the launch of Prometrium®, we are now going beyond being a
standard provider of generic products,” commented Tina
Guilder, CEO of the Company. “This is our first branded product
launch and we hope to offer more mature brands to support our vision to
provide affordable medicines that help secure long-term access to
healthcare for people around the world.”
About Virtus Pharmaceuticals, Inc.
Virtus Pharmaceuticals’ mission is to be the leading specialty niche
pharmaceutical company providing the highest quality products through
experienced leadership, innovative approaches and outstanding customer
service. For more information, please visit the Company’s Web site at www.virtusrx.com.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused
exclusively on leveraged buyouts in the healthcare and life sciences
industries. Linden’s strategy is based upon three elements: (i)
healthcare and life science industry specialization, (ii) integrated
private equity and operating expertise, and (iii) strategic
relationships with large corporations. Linden invests in middle market
platforms in the medical products, specialty distribution,
pharmaceutical, and services segments of healthcare.
Virtus Pharmaceuticals, Inc.
Tina Guilder, CEO, 813-283-1344